{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T09:29:52Z","timestamp":1769160592144,"version":"3.49.0"},"reference-count":32,"publisher":"Frontiers Media SA","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2014.00055","type":"journal-article","created":{"date-parts":[[2014,3,18]],"date-time":"2014-03-18T14:58:41Z","timestamp":1395154721000},"source":"Crossref","is-referenced-by-count":27,"title":["Molecular Therapeutic Approaches for Pediatric Acute Myeloid Leukemia"],"prefix":"10.3389","volume":"4","author":[{"given":"Sarah K.","family":"Tasian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica A.","family":"Pollard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Aplenc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2014,3,18]]},"reference":[{"issue":"3","key":"B1","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1634\/theoncologist.12-3-341","article-title":"Prognostic factors and risk-based therapy in pediatric acute myeloid leukemia","volume":"12","author":"Meshinchi","year":"2007","journal-title":"Oncologist"},{"issue":"5","key":"B2","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1200\/JCO.2010.30.7405","article-title":"Biology, risk stratification, and therapy of pediatric acute leukemias: an update","volume":"29","author":"Pui","year":"2011","journal-title":"J Clin Oncol"},{"issue":"7","key":"B3","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1038\/leu.2013.106","article-title":"Novel therapies for children with acute myeloid leukaemia","volume":"27","author":"Moore","year":"2013","journal-title":"Leukemia"},{"issue":"16","key":"B4","doi-asserted-by":"publisher","first-page":"3187","DOI":"10.1182\/blood-2012-03-362608","article-title":"Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel","volume":"120","author":"Creutzig","year":"2012","journal-title":"Blood"},{"issue":"5","key":"B5","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1002\/pbc.24464","article-title":"Epidemiology of childhood acute myeloid leukemia","volume":"60","author":"Puumala","year":"2013","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"B6","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1007\/s11899-010-0060-z","article-title":"Prognostic factors in pediatric acute myeloid leukemia","volume":"5","author":"Radhi","year":"2010","journal-title":"Curr Hematol Malig Rep"},{"issue":"4","key":"B7","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1002\/pbc.23397","article-title":"Genetic and epigenetic similarities and differences between childhood and adult AML","volume":"58","author":"Juhl-Christensen","year":"2012","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"B8","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1053\/j.seminhematol.2013.09.003","article-title":"Somatic characterization of pediatric acute myeloid leukemia using next-generation sequencing","volume":"50","author":"Schuback","year":"2013","journal-title":"Semin Hematol"},{"issue":"16","key":"B9","doi-asserted-by":"publisher","first-page":"3705","DOI":"10.1182\/blood-2011-12-398370","article-title":"Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML","volume":"119","author":"Pollard","year":"2012","journal-title":"Blood"},{"issue":"1","key":"B10","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1021\/bc010021y","article-title":"Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia","volume":"13","author":"Hamann","year":"2002","journal-title":"Bioconjug Chem"},{"issue":"10","key":"B11","doi-asserted-by":"publisher","first-page":"4168","DOI":"10.1182\/blood-2006-09-047399","article-title":"CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy","volume":"109","author":"Walter","year":"2007","journal-title":"Blood"},{"issue":"4","key":"B12","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1309\/1WMW-CMXX-4WN4-T55U","article-title":"Differences in CD33 intensity between various myeloid neoplasms","volume":"118","author":"Jilani","year":"2002","journal-title":"Am J Clin Pathol"},{"issue":"13","key":"B13","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1200\/JCO.2001.19.13.3244","article-title":"Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse","volume":"19","author":"Sievers","year":"2001","journal-title":"J Clin Oncol"},{"issue":"7","key":"B14","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1002\/cncr.21326","article-title":"Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence","volume":"104","author":"Larson","year":"2005","journal-title":"Cancer"},{"issue":"13","key":"B15","doi-asserted-by":"publisher","first-page":"4277","DOI":"10.1182\/blood-2003-05-1620","article-title":"A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia","volume":"102","author":"Kell","year":"2003","journal-title":"Blood"},{"issue":"3","key":"B16","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1159\/000075606","article-title":"Gemtuzumab ozogamicin (Mylotarg) in children with refractory or relapsed acute myeloid leukemia","volume":"27","author":"Reinhardt","year":"2004","journal-title":"Onkologie"},{"issue":"5","key":"B17","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1111\/j.1365-2141.2009.08011.x","article-title":"Salvage treatment for children with refractory first or second relapse of acute myeloid leukaemia with gemtuzumab ozogamicin: results of a phase II study","volume":"148","author":"Zwaan","year":"2010","journal-title":"Br J Haematol"},{"issue":"2","key":"B18","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.bbmt.2011.11.007","article-title":"A Phase I study of gemtuzumab ozogamicin (GO) in combination with busulfan and cyclophosphamide (Bu\/Cy) and allogeneic stem cell transplantation in children with poor-risk CD33+ AML: a new targeted immunochemotherapy myeloablative conditioning (MAC) regimen","volume":"18","author":"Satwani","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"19 Pt 2","key":"B19","doi-asserted-by":"publisher","first-page":"7164s","DOI":"10.1158\/1078-0432.CCR-1004-0018","article-title":"Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia","volume":"11","author":"Roman","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"4","key":"B20","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1182\/blood-2004-10-3821","article-title":"Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia","volume":"106","author":"Arceci","year":"2005","journal-title":"Blood"},{"issue":"8","key":"B21","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1177\/0091270004267595","article-title":"Pharmacokinetics of gemtuzumab ozogamicin as a single-agent treatment of pediatric patients with refractory or relapsed acute myeloid leukemia","volume":"44","author":"Buckwalter","year":"2004","journal-title":"J Clin Pharmacol"},{"issue":"22","key":"B22","doi-asserted-by":"publisher","first-page":"4036","DOI":"10.1002\/cncr.28334","article-title":"Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia","volume":"119","author":"O\u00e2\u20ac\u2122Hear","year":"2013","journal-title":"Cancer"},{"issue":"14","key":"B23","doi-asserted-by":"publisher","first-page":"2390","DOI":"10.1200\/JCO.2007.13.0096","article-title":"Safety and efficacy of gemtuzumab ozogamicin in combination with chemotherapy for pediatric acute myeloid leukemia: a report from the Children\u00e2\u20ac\u2122s Oncology Group","volume":"26","author":"Aplenc","year":"2008","journal-title":"J Clin Oncol"},{"issue":"3","key":"B24","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1002\/cncr.26190","article-title":"AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children\u00e2\u20ac\u2122s Oncology Group","volume":"118","author":"Cooper","year":"2012","journal-title":"Cancer"},{"issue":"5","key":"B25","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1182\/blood-2012-03-416701","article-title":"Gemtuzumab ozogamicin as postconsolidation therapy does not prevent relapse in children with AML: results from NOPHO-AML 2004","volume":"120","author":"Hasle","year":"2012","journal-title":"Blood"},{"issue":"21","key":"B26","first-page":"355","article-title":"Gemtuzumab ozogamicin (GO) in children with de novo acute myeloid leukemia (AML) improves event-free survival (EFS) by reducing relapse risk \u00e2\u20ac\u201c results from the randomized Phase III Children\u00e2\u20ac\u2122s Oncology Group (COG) trial, AAML0531","volume":"122","author":"Gamis","year":"2013","journal-title":"Blood"},{"issue":"21","key":"B27","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1182\/blood.V122.21.491.491","article-title":"Negative prognostic impact of high CD33 expression is negated with the use of gemtuzumab ozogamicin: a report from the Children\u00e2\u20ac\u2122s Oncology Group","volume":"122","author":"Pollard","year":"2013","journal-title":"Blood"},{"issue":"24","key":"B28","doi-asserted-by":"publisher","first-page":"4854","DOI":"10.1182\/blood-2013-01-466706","article-title":"A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia","volume":"121","author":"Petersdorf","year":"2013","journal-title":"Blood"},{"issue":"32","key":"B29","doi-asserted-by":"publisher","first-page":"3921","DOI":"10.1200\/JCO.2012.43.0132","article-title":"Gemtuzumab ozogamicin: time to resurrect?","volume":"30","author":"Ravandi","year":"2012","journal-title":"J Clin Oncol"},{"issue":"4","key":"B30","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1200\/JCO.2010.31.4310","article-title":"Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial","volume":"29","author":"Burnett","year":"2011","journal-title":"J Clin Oncol"},{"issue":"32","key":"B31","doi-asserted-by":"publisher","first-page":"3924","DOI":"10.1200\/JCO.2012.42.2964","article-title":"Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia","volume":"30","author":"Burnett","year":"2012","journal-title":"J Clin Oncol"},{"issue":"1","key":"B32","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/leu.2012.229","article-title":"The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison","volume":"27","author":"Burnett","year":"2013","journal-title":"Leukemia"}],"container-title":["Frontiers in Oncology"],"original-title":[],"deposited":{"date-parts":[[2020,8,16]],"date-time":"2020-08-16T12:00:10Z","timestamp":1597579210000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fonc.2014.00055\/abstract"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,18]]},"references-count":32,"URL":"https:\/\/doi.org\/10.3389\/fonc.2014.00055","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,18]]}}}